<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00860977</url>
  </required_header>
  <id_info>
    <org_study_id>CTN 240</org_study_id>
    <secondary_id>ISRCTN66756285</secondary_id>
    <nct_id>NCT00860977</nct_id>
  </id_info>
  <brief_title>Can Valacyclovir Delay the Need for Initiation of Human Immunodeficiency Virus (HIV) Treatment in HIV-infected Individuals?</brief_title>
  <acronym>VALIDATE</acronym>
  <official_title>VALacyclovir In Delaying Antiretroviral Treatment Entry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CIHR Canadian HIV Trials Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a multicentre, randomized, placebo-controlled, fully blinded, clinical trial of
      twice daily oral valacyclovir 500mg versus placebo with the goal of delaying the need for
      initiating HAART among HIV infected individuals who neither use nor require HAART, and who
      have not used chronic suppressive anti-HSV therapy for at least the 6 months prior to study
      initiation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2010</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>annual rate of change in CD4 count, calculated as the slope of participants' CD4 count change / time.</measure>
    <time_frame>up to 5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>time from baseline until reaching the composite of either a CD4 cell count ≤350 cells/mm3 measured on two consecutive occasions at least 1 month apart, or initiation of HAART for any reason, whichever occurs first.</measure>
    <time_frame>up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annual rate of change in the CD4 cell count percentage, calculated as the slope of the participants' CD4 count percentage change over time</measure>
    <time_frame>up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Log10 plasma HIV viral load at 12, 24 and 36 months of follow-up</measure>
    <time_frame>up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-emergent adverse events and laboratory abnormalities (CBC, serum creatinine)</measure>
    <time_frame>up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of episodes of HSV reactivations at any anatomic site</measure>
    <time_frame>up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of microbiologically confirmed flares of HSV during the trial that are caused by laboratory-confirmed acyclovir-resistant HSV</measure>
    <time_frame>up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall quality of life as measured by the MOS-HIV questionnaire at each 6-monthly time point</measure>
    <time_frame>up to 5 years</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>analysis of inflammatory markers in HIV disease progression, HIV Resistance Mutations and other herpesvirus serologies</measure>
    <time_frame>up to 6 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>genetic testing of HLA-B*5701 and HLA-B*5703 status, and future genetic markers related to HIV disease progression and the impact of herpes and valacyclovir</measure>
    <time_frame>up to 5 years</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">202</enrollment>
  <condition>HIV Infection</condition>
  <condition>Herpes Simplex Type II</condition>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Odourless placebo tablet identical to valacyclovir in appearance and taste, to be taken twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Valacyclovir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral valacyclovir 500mg twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>valacyclovir</intervention_name>
    <description>oral valacyclovir 500mg twice daily</description>
    <arm_group_label>Valacyclovir</arm_group_label>
    <other_name>Valtrex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Odourless placebo tablet identical to valacyclovir in appearance and taste, to be taken twice daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  adult (aged 18 years or older or as per Local/Provincial Guidelines)

          -  documented HIV-1 infection (determined by EIA and Western blot, sites' standard assays
             are acceptable if approved in advance by the PIs for the study, Dr. Darrell Tan and/or
             Dr. Sharon Walmsley)

          -  no use of chronic anti-HSV therapy for the past 6 months, and not anticipated to
             require chronic anti-HSV therapy during the study

          -  antiretroviral naïve (no more than 14 days of total prior ARV exposure)

          -  CD4 count within the 400-900 cells/mm3 range (inclusive) on two consecutive occasions,
             with at least one measurement within 30 days of initiating trial (baseline visit)

          -  does not meet recommendations for initiating ARV therapy according to current
             guidelines

        Exclusion Criteria:

          -  pregnancy or actively planning to become pregnant

          -  receiving chemotherapy, chronic steroid therapy or other immunomodulatory medications
             (e.g. interferon, azathioprine, methotrexate, TNF-alpha antagonists, etc.)

          -  Estimated creatinine clearance &lt;30 mL/min

          -  Other medical condition likely to cause death within 24 months

          -  Enrolled in a therapeutic HIV vaccine or immunotherapy trial

          -  Enrolled in another trial investigating the impact of another intervention on HIV
             disease progression

          -  HIV elite controller (EC), phenotypically defined here as documented duration of HIV
             infection of ≥5 years, a persistent CD4 cell count ≥500 cells/mm3, and a persistent
             plasma HIV viral load of &lt;1000 copies/mL in the absence of antiretroviral therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sharon L Walmsley, MD FRCPC MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Health Network, Toronto</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Darrell HS Tan, MD FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Health Network, Toronto</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fundación Huesped</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1202ABB</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Pesquisa Clínica Evandro Chagas</name>
      <address>
        <city>Rio de Janeiro</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ambulatorio de Infectologia da UNIFESP</name>
      <address>
        <city>Sao Paulo</city>
        <zip>04040-002</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Referencia e Treinamento em DST/AIDS</name>
      <address>
        <city>Sao Paulo</city>
        <zip>04121-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2C8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>B.C. Women's Hospital &amp; Health Centre - Oak Tree Clinic</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6H 1N1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vancouver Infectious Disease Clinic</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 2C7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cool Aid Community Health Centre</name>
      <address>
        <city>VIctoria</city>
        <state>British Columbia</state>
        <zip>V8W 1M8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CDHA, QEII Health Sciences Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 2Y9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McMaster University Health Sciences Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital, General Campus Divsions of Infectious Diseases</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Ottawa Health Services</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1N 6N5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Science Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M2N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Clair Medical Associates</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4K 1N1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maple Leaf Medical Clinic</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Health Network</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Windsor Regional Hospital</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8W 1E3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montreal Chest Institute</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2X 2P4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de l'Université de Montréal</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Quebec-Pavillon CHUL</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4G2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brighton &amp; Sussex University Hospitals NHS Trust</name>
      <address>
        <city>Brighton</city>
        <zip>BN2 1ES</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guy's and St. Thomas' NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SE1 7EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Stephen's AIDS Trust</name>
      <address>
        <city>London</city>
        <zip>SW10 9NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Mary's Hospital</name>
      <address>
        <city>London</city>
        <zip>W2 1NY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.hivnet.ubc.ca/clinical-trials/ctn240/</url>
    <description>CIHR Canadian HIV Trials Network - CTN 240</description>
  </link>
  <reference>
    <citation>Tan DH, Raboud JM, Kaul R, Grinsztejn B, Cahn P, Walmsley SL. Can herpes simplex virus type 2 suppression slow HIV disease progression: a study protocol for the VALacyclovir In Delaying Antiretroviral Treatment Entry (VALIDATE) trial. Trials. 2010 Nov 24;11:113. doi: 10.1186/1745-6215-11-113.</citation>
    <PMID>21106086</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 11, 2009</study_first_submitted>
  <study_first_submitted_qc>March 11, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2009</study_first_posted>
  <last_update_submitted>March 2, 2018</last_update_submitted>
  <last_update_submitted_qc>March 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Herpes simplex virus type II</keyword>
  <keyword>Genital herpes</keyword>
  <keyword>Treatment Naive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>Herpes Simplex</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valacyclovir</mesh_term>
    <mesh_term>Acyclovir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

